{"nctId":"NCT01352221","briefTitle":"Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)","startDateStruct":{"date":"2011-08"},"conditions":["Iron Deficiency Anaemia","Inflammatory Bowel Disease","Crohn's Disease"],"count":128,"armGroups":[{"label":"ST10","type":"EXPERIMENTAL","interventionNames":["Drug: ST10"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo oral capsule"]}],"interventions":[{"name":"ST10","otherNames":["Ferric Trimaltol","Ferric Maltol"]},{"name":"Placebo oral capsule","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Competency to understand and sign the IEC/IRB approved informed consent form prior to any study mandated procedure, and willing/able to comply with study requirements\n* Age ≥ 18 years\n* Current diagnosis of quiescent CD as defined by CDAI score of \\< 220\n* Current diagnosis of IDA as defined by Hb ≥ 9.5 g/dl and \\<12.0 g/dl for women and ≥ 9.5 g/dl and \\<13.0 g/dl for men; ferritin \\< 30 µg/l\n* Prior OFP failure as defined per protocol\n* If receiving protocol-allowed immunosuppressant must be on stable dose\n* Females of childbearing potential must agree to use a reliable method of contraception\n\nExclusion Criteria:\n\n* Anaemia due to any cause other than iron deficiency\n* Intramuscular or intravenous injection or administration of depot iron preparation, blood infusions, or erythropoietin within 3 months\n* Oral iron supplementation use within 1 month\n* Use of immunosuppressant with known effect of anaemia induction within 1 month\n* Vitamin B12 or Folic Acid injection/infusion within 4 weeks\n* Untreated Vitamin B-12 or Folic Acid deficiency\n* Known hypersensitivity or allergy to ST10-021 or components of the study medication, or contraindication for treatment with iron preparations\n* Other chronic or acute inflammatory or infectious diseases\n* Creatinine \\> 2.0 mg/dl\n* AST or ALT levels ≥ 5 times the upper limit of normal\n* Cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject\n* History of malignancy within the past 5 years (except in situ removal of basal cell carcinoma)\n* Significant neurologic or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately that might interfere with treatment compliance, study conduct or interpretation of the results\n* Participation in another interventional clinical study within 30 days or during the study\n* Inmates of a psychiatric ward, prison, or other state institution\n* Investigator or any other team member involved directly or indirectly in the conduct of the clinical study\n* Scheduled or expected hospitalization and/or surgery during the course of the study\n* Females who are pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Haemoglobin (Hb) Concentration From Baseline to Week 12 (Full Analysis Set, FAS)","description":"Primary efficacy endpoint, defined as the change in Hb concentration from Baseline to Week 12. Baseline was defined as the pre-dose Hb concentration measured at the Randomisation Visit (Week 0). Missing Randomisation Hb values were replaced by Screening Hb values, if the randomisation was within the protocol-specified window. Hb concentration (g/dL) was analysed by a central laboratory from blood samples collected at every clinic visit: Screening, Randomisation (Week 0), Weeks 4, 8, 12, 14, 16, 20, 24, 36, 48, 64, Weeks 14 to 64 were open-label. The baseline, absolute concentration and change from baseline in Hb at all post-randomisation visits were listed and summarised by week using descriptive statistics. An analysis of covariance (ANCOVA) was used to analyse the primary endpoint; this included treatment, gender and disease as factors and baseline Hb as a covariate.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.26","spread":"1.184"},{"groupId":"OG001","value":"0.01","spread":"0.764"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects That Achieved ≥1 g/dL Change From Baseline in Hb Concentration at Week 12 (Full Analysis Set, FAS)","description":"Logistic regression analysis of proportion of subjects that achieved ≥1 g/dL change from baseline in Hb concentration at Week 12 in the double-blind phase","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects That Achieved ≥2 g/dL Change From Baseline in Hb Concentration at Week 12 (Full Analysis Set, FAS)","description":"Logistic regression analysis of proportion of subjects that achieved ≥2 g/dL change from baseline in Hb concentration at Week 12 in the double-blind phase","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects That Achieved Hb Concentration Within Normal Range at Week 12 (Full Analysis Set, FAS)","description":"Logistic regression analysis of proportion of subjects that achieved Hb concentration within normal range at Week 12 end of double-blind phase","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hb Concentration From Baseline to Week 4 (Full Analysis Set, FAS)","description":"ANCOVA analysis of the change in Hb concentration from Baseline to Week 4 of the double-blind phase - Full Analysis Set, multiple imputation","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"0.676"},{"groupId":"OG001","value":"0","spread":"0.67"}]}]}]},{"type":"SECONDARY","title":"Change in Hb Concentration From Baseline to Week 8 (Full Analysis Set, FAS)","description":"ANCOVA analysis of Change in Hb concentration from Baseline to Week 8 of double-blind phase - FAS, multiple imputation","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.79","spread":"1.037"},{"groupId":"OG001","value":"0.04","spread":"0.722"}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin Concentration From Baseline to Week 16 (Full Analysis Set, FAS)","description":"Change in Haemoglobin Concentration from Baseline to Week 16 (FAS), after 12-week double-blind phase and first 4 weeks of open-label ST10 treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"1.281"},{"groupId":"OG001","value":"1.04","spread":"1.023"}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin Concentration From Baseline to Week 20 (Full Analysis Set, FAS)","description":"Change in Haemoglobin Concentration from Baseline to Week 20 (FAS), after 12-week double-blind phase and then 8 weeks of open-label ST10 treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.45","spread":"1.213"},{"groupId":"OG001","value":"1.46","spread":"1.056"}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin Concentration From Baseline to Week 24 (Full Analysis Set, FAS)","description":"Change in Haemoglobin Concentration from Baseline to Week 24 (FAS), after 12-week double-blind phase and then 12 weeks of open-label ST10 treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":"1.127"},{"groupId":"OG001","value":"1.87","spread":"1.195"}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin Concentration From Baseline to Week 36 (Full Analysis Set, FAS)","description":"Change in Haemoglobin Concentration from Baseline to Week 36 (FAS), after 12-week double-blind phase and then 24 weeks of open-label ST10 treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.85","spread":"1.227"},{"groupId":"OG001","value":"2.17","spread":"1.048"}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin Concentration From Baseline to Week 48 (Full Analysis Set, FAS)","description":"Change in Haemoglobin Concentration from Baseline to Week 48 (FAS), after 12-week double-blind phase and then 36 weeks of open-label ST10 treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.09","spread":"1.339"},{"groupId":"OG001","value":"2.0","spread":"1.191"}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)","description":"Change in Haemoglobin Concentration from Baseline to Week 64 (FAS), after 12-week double-blind phase and then 52 weeks of open-label ST10 treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.07","spread":"1.457"},{"groupId":"OG001","value":"2.19","spread":"1.605"}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin Concentration From Baseline to Week 64 EOS (Full Analysis Set, FAS)","description":"Change in Haemoglobin Concentration from Baseline to Week 64 EOS (FAS) - Week 64 was re-categorised as Week 64 EOS for those subjects who withdrew from the study early and the 'Week 64' visit was outside the visit window of 64 weeks ± 2 days","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"1.713"},{"groupId":"OG001","value":"0.52","spread":"1.417"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 16 (Full Analysis Set, FAS)","description":"Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 16 (Full Analysis Set), after 12-week double-blind phase and first 4 weeks of open-label ST10 treatment","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 36 (Full Analysis Set, FAS)","description":"Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 36 (Full Analysis Set), after 12-week double-blind phase and 24 weeks of open-label ST10 treatment","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"29","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 64 (Full Analysis Set, FAS)","description":"Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 64 (Full Analysis Set), after 12-week double-blind phase and 52 weeks of open-label ST10 treatment","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"30","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin Concentration From Baseline to Week 12 (Per Protocol Analysis Set, PPAS)","description":"ANCOVA sensitivity analysis of the Primary efficacy endpoint analysis on the PPAS - Change in Haemoglobin Concentration from Baseline to Week 12","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"0.13"},{"groupId":"OG001","value":"0.05","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin Concentration From Baseline to Week 12 (Full Analysis Set [FAS] LOCF)","description":"ANCOVA sensitivity analysis of the Primary efficacy endpoint analysis on the FAS LOCF - Change in Haemoglobin Concentration from Baseline to Week 12","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":"0.12"},{"groupId":"OG001","value":"-0.03","spread":"0.12"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Serum Ferritin Concentration From Baseline to Week 12 (Full Analysis Set, FAS)","description":"Change in serum Ferritin concentration from Baseline to Week 12 (Full Analysis Set), after 12-week double-blind phase","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":"28.3"},{"groupId":"OG001","value":"1.2","spread":"7.85"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Serum TSAT% From Baseline to Week 12 (Full Analysis Set, FAS)","description":"Change in serum TSAT% from Baseline to Week 12 (FAS), after 12-week double-blind phase","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"20.17"},{"groupId":"OG001","value":"-0.4","spread":"7.82"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Serum Ferritin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)","description":"Change in serum Ferritin concentration from Baseline to Week 64 (FAS), after 12-week double-blind phase and 52 weeks open-label ST10 treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","spread":"93.35"},{"groupId":"OG001","value":"36.6","spread":"46.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Serum TSAT% From Baseline to Week 64 (Full Analysis Set, FAS)","description":"Change in serum TSAT% from Baseline to Week 64 (Full Analysis Set), after 12-week double-blind phase and 52 weeks open-label ST10 treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":"12.46"},{"groupId":"OG001","value":"17.7","spread":"16.2"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 12 (Full Analysis Set, FAS)","description":"Irritable Bowel Disease Questionnaire (IBDQ) score at Week 12 (FAS), end of double-blind phase.\n\nThe IBDQ was developed as an activity index for determining the effect of Crohn's disease symptoms on perceived quality of life. It is a 32-item questionnaire with four dimensions: bowel function, emotional status, systemic symptoms and social function. Total IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life. The score of patients in remission usually is between 170 and 190.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178.3","spread":"32.36"},{"groupId":"OG001","value":"176.3","spread":"31.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 64 (Full Analysis Set, FAS)","description":"Irritable Bowel Disease Questionnaire (IBDQ) score at Week 64 (FAS), after 12-week double-blind phase and 52 weeks of open-label ST10 treatment.\n\nThe IBDQ was developed as an activity index for determining the effect of Crohn's disease symptoms on perceived quality of life. It is a 32-item questionnaire with four dimensions: bowel function, emotional status, systemic symptoms and social function. Total IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life. The score of patients in remission usually is between 170 and 190.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"180.7","spread":"30.14"},{"groupId":"OG001","value":"177.2","spread":"36.97"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 12 (Full Analysis Set, FAS)","description":"Change from baseline (randomisation) in Crohn's Disease Activity Index (CDAI) score at Week 12 (FAS), end of double-blind phase (in subjects with CD).\n\nThe CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease. CDAI score can range from 0 to approximately 600. Traditionally, for clinical trials, clinical remission is defined as a CDAI score \\<150, clinical response is a decrease in CDAI score of 70-100. Mildly active Crohn's disease is defined as a CDAI score 150-220, moderate-severe Crohn's is typically a CDAI 220-450, and severe disease is defined as a CDAI \\>450.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 64 (Full Analysis Set, FAS)","description":"Change from baseline in Crohn's Disease Activity Index (CDAI) score at Week 64 (FAS), after 12-week double blind phase and 52 weeks open-label ST10 treatment (in participants with CD only).\n\nThe CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease. CDAI score can range from 0 to approximately 600. Traditionally, for clinical trials, clinical remission is defined as a CDAI score \\<150, clinical response is a decrease in CDAI score of 70-100. Mildly active Crohn's disease is defined as a CDAI score 150-220, moderate-severe Crohn's is typically a CDAI 220-450, and severe disease is defined as a CDAI \\>450.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.6","spread":null},{"groupId":"OG001","value":"-1.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":64},"commonTop":["Nasopharyngitis","Abdominal pain","Diarrhoea","Crohn's disease","Colitis ulcerative"]}}}